13.01.20: Not intended for U.S. and UK Media

Bayer and Daré Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®Underlining Bayer's commitment in the field of women's health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit rangemehr ...
Source: Bayer IR Newsfeed: Events - Category: Pharmaceuticals Source Type: news